{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T12:52:44Z","timestamp":1791550364119,"version":"4.3.4"},"reference-count":50,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":194,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ghadvances.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gastro Hep Advances"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.gastha.2026.101070","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T15:13:16Z","timestamp":1784560396000},"page":"101070","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Clinical Efficacy of Food and Drug Administration\u2013Approved Budesonide Oral Suspension Across Histologic, Endoscopic, and Symptomatic Outcomes"],"prefix":"10.1016","volume":"5","author":[{"given":"Gustaf N.","family":"Hendrick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefani","family":"Aleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra A.","family":"Weir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Langley B.","family":"Barnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean S.","family":"LaFata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjun K.","family":"Juneja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelica R.","family":"Lackey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassie B.","family":"Almond","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shivani","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambika V.","family":"Viswanathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel L.","family":"Sperling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle S.","family":"Russin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie J.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor S.","family":"Barlowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walker D.","family":"Redd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cary C.","family":"Cotton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig C.","family":"Reed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1167-1101","authenticated-orcid":false,"given":"Evan S.","family":"Dellon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.gastha.2026.101070_bib1","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1053\/j.gastro.2025.09.030","article-title":"Epidemiology, natural history, and treatment of eosinophilic gastrointestinal diseases","volume":"170","author":"Visaggi","year":"2026","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastha.2026.101070_bib2","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1053\/j.gastro.2018.07.009","article-title":"Updated international consensus diagnostic criteria for eosinophilic esophagitis: proceedings of the AGREE conference","volume":"155","author":"Dellon","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastha.2026.101070_bib3","doi-asserted-by":"crossref","first-page":"31","DOI":"10.14309\/ajg.0000000000003194","article-title":"ACG clinical guideline: diagnosis and management of eosinophilic esophagitis","volume":"120","author":"Dellon","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gastha.2026.101070_bib4","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.cgh.2024.09.031","article-title":"Prevalence and costs of eosinophilic esophagitis in the United States","volume":"23","author":"Thel","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.gastha.2026.101070_bib5","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/ajg.2014.316","article-title":"Health-care utilization, costs, and the burden of disease related to eosinophilic esophagitis in the United States","volume":"110","author":"Jensen","year":"2015","journal-title":"Am J Gastroenterol"},{"issue":"6","key":"10.1016\/j.gastha.2026.101070_bib6","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1053\/j.gastro.2020.02.038","article-title":"AGA Institute and the Joint Task Force on Allergy-Immunology Practice Parameters clinical guidelines for the management of eosinophilic esophagitis","volume":"158","author":"Hirano","year":"2020","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.gastha.2026.101070_bib7","first-page":"90","article-title":"Treatment of eosinophilic esophagitis with inhaled corticosteroids","volume":"27","author":"Faubion","year":"1998","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"3","key":"10.1016\/j.gastha.2026.101070_bib8","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.jaci.2005.05.011","article-title":"Topical viscous budesonide suspension for treatment of eosinophilic esophagitis","volume":"116","author":"Aceves","year":"2005","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.gastha.2026.101070_bib9","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1053\/j.gastro.2014.04.019","article-title":"Efficacy, dose reduction, and resistance to high-dose fluticasone in patients with eosinophilic esophagitis","volume":"147","author":"Butz","year":"2014","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.gastha.2026.101070_bib10","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1053\/j.gastro.2010.07.048","article-title":"Budesonide is effective in adolescent and adult patients with active eosinophilic esophagitis","volume":"139","author":"Straumann","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastha.2026.101070_bib11","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.1016\/j.cgh.2020.08.027","article-title":"Effectiveness and safety of high- vs low-dose swallowed topical steroids for maintenance treatment of eosinophilic esophagitis: a multicenter observational study","volume":"19","author":"Greuter","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.gastha.2026.101070_bib12","doi-asserted-by":"crossref","DOI":"10.1038\/ctg.2017.27","article-title":"Diminishing effectiveness of long-term maintenance topical steroid therapy in PPI non-responsive eosinophilic esophagitis","volume":"8","author":"Eluri","year":"2017","journal-title":"Clin Transl Gastroenterol"},{"key":"10.1016\/j.gastha.2026.101070_bib13","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/nrgastro.2017.56","article-title":"Management of refractory eosinophilic oesophagitis","volume":"14","author":"Dellon","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.gastha.2026.101070_bib14","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/MCG.0000000000002006","article-title":"Satisfaction with and adherence to off-label corticosteroids in adolescents and adults with eosinophilic esophagitis: results of a web-based survey in the United States","volume":"59","author":"Gold","year":"2025","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.gastha.2026.101070_bib15","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.clinre.2018.03.003","article-title":"Individuals affected by eosinophilic gastrointestinal disorders have complex unmet needs and frequently experience unique barriers to care","volume":"42","author":"Hiremath","year":"2018","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.gastha.2026.101070_bib16","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1053\/j.gastro.2012.04.049","article-title":"Viscous topical is more effective than nebulized steroid therapy for patients with eosinophilic esophagitis","volume":"143","author":"Dellon","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastha.2026.101070_bib17","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1053\/j.gastro.2019.03.025","article-title":"Efficacy of budesonide orodispersible tablets as induction therapy for eosinophilic esophagitis in a randomized placebo-controlled trial","volume":"157","author":"Lucendo","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastha.2026.101070_bib18","doi-asserted-by":"crossref","first-page":"2485","DOI":"10.1016\/j.cgh.2022.02.013","article-title":"Fluticasone propionate orally disintegrating tablet (APT-1011) for eosinophilic esophagitis: randomized controlled trial","volume":"20","author":"Dellon","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.gastha.2026.101070_bib19","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/apt.18443","article-title":"Clinical trial: safety and efficacy of a novel oesophageal delivery system for topical corticosteroids versus placebo in the treatment of eosinophilic oesophagitis","volume":"61","author":"Lucendo","year":"2025","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastha.2026.101070_bib20","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/j.cgh.2021.04.022","article-title":"Budesonide oral suspension improves outcomes in patients with eosinophilic esophagitis: results from a phase 3 trial","volume":"20","author":"Hirano","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.gastha.2026.101070_bib21","doi-asserted-by":"crossref","first-page":"16","DOI":"10.14309\/ajg.0000000000003090","article-title":"Budesonide oral suspension: expanding the toolkit for eosinophilic esophagitis","volume":"120","author":"Chang","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gastha.2026.101070_bib22","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1016\/j.cgh.2021.06.020","article-title":"Long-term treatment of eosinophilic esophagitis with budesonide oral suspension","volume":"20","author":"Dellon","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastha.2026.101070_bib23","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.cgh.2018.05.051","article-title":"Safety and efficacy of budesonide oral suspension maintenance therapy in patients with eosinophilic esophagitis","volume":"17","author":"Dellon","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastha.2026.101070_bib24","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1053\/j.gastro.2016.11.021","article-title":"Budesonide oral suspension improves symptomatic, endoscopic, and histologic parameters compared with placebo in patients with eosinophilic esophagitis","volume":"152","author":"Dellon","year":"2017","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.gastha.2026.101070_bib25","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1016\/j.cgh.2024.12.024","article-title":"Long-term safety and efficacy of budesonide oral suspension for eosinophilic esophagitis: a 4-year, phase 3, open-label study","volume":"23","author":"Dellon","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastha.2026.101070_bib26","doi-asserted-by":"crossref","DOI":"10.1177\/17562848241307602","article-title":"Effect of randomized treatment withdrawal of budesonide oral suspension on clinically relevant efficacy outcomes in patients with eosinophilic esophagitis: a post hoc analysis","volume":"17","author":"Dellon","year":"2024","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.gastha.2026.101070_bib27","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.gie.2015.11.019","article-title":"The extremely narrow-caliber esophagus is a treatment-resistant subphenotype of eosinophilic esophagitis","volume":"83","author":"Eluri","year":"2016","journal-title":"Gastrointest Endosc"},{"issue":"2","key":"10.1016\/j.gastha.2026.101070_bib28","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/ajg.2015.399","article-title":"Outcomes of esophageal dilation in eosinophilic esophagitis: safety, efficacy, and persistence of the fibrostenotic phenotype","volume":"111","author":"Runge","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.gastha.2026.101070_bib29","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1016\/j.cgh.2024.10.016","article-title":"Daily or twice daily treatment with topical steroids results in similar responses in eosinophilic esophagitis","volume":"23","author":"Reed","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastha.2026.101070_bib30","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1016\/j.cgh.2025.01.015","article-title":"Worsening disease severity as measured by I-SEE associates with decreased treatment response to topical steroids in eosinophilic esophagitis patients","volume":"23","author":"Reed","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastha.2026.101070_bib31","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/ajg.2011.342","article-title":"Influence of race and gender on the presentation of eosinophilic esophagitis","volume":"107","author":"Sperry","year":"2012","journal-title":"Am J Gastroenterol"},{"issue":"1","key":"10.1016\/j.gastha.2026.101070_bib32","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1053\/j.gastro.2022.03.025","article-title":"A clinical severity index for eosinophilic esophagitis: development, consensus, and future directions","volume":"163","author":"Dellon","year":"2022","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastha.2026.101070_bib33","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1016\/j.cgh.2023.03.047","article-title":"A newly proposed severity index for eosinophilic esophagitis is associated with baseline clinical features and successful treatment response","volume":"10","author":"Cotton","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastha.2026.101070_bib34","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.17554\/j.issn.2224-3992.2018.07.750","article-title":"Compounded oral viscous budesonide is effective and provides a durable response in eosinophilic esophagitis","volume":"7","author":"Reed","year":"2018","journal-title":"J Gastroenterol Hepatol Res"},{"key":"10.1016\/j.gastha.2026.101070_bib35","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1136\/gutjnl-2011-301817","article-title":"Endoscopic assessment of the oesophageal features of eosinophilic oesophagitis: validation of a novel classification and grading system","volume":"62","author":"Hirano","year":"2013","journal-title":"Gut"},{"key":"10.1016\/j.gastha.2026.101070_bib36","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1016\/j.cgh.2019.01.030","article-title":"A conceptual approach to understanding treatment response in eosinophilic esophagitis","volume":"17","author":"Dellon","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastha.2026.101070_bib37","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.17554\/j.issn.2224-3992.2015.04.562","article-title":"Evaluation of histologic cutpoints for treatment response in eosinophilic esophagitis","volume":"4","author":"Wolf","year":"2015","journal-title":"J Gastroenterol Hepatol Res"},{"key":"10.1016\/j.gastha.2026.101070_bib38","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.cgh.2017.09.046","article-title":"Optimal histologic cutpoints for treatment response in patients with eosinophilic esophagitis: analysis of data from a prospective cohort study","volume":"16","author":"Reed","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.gastha.2026.101070_bib39","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.gie.2022.05.013","article-title":"Endoscopic approach to eosinophilic esophagitis: American Society for Gastrointestinal Endoscopy Consensus Conference","volume":"96","author":"Aceves","year":"2022","journal-title":"Gastrointest Endosc"},{"key":"10.1016\/j.gastha.2026.101070_bib40","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.gie.2022.01.014","article-title":"Reliability and responsiveness of endoscopic disease activity assessment in eosinophilic esophagitis","volume":"95","author":"Ma","year":"2022","journal-title":"Gastrointest Endosc"},{"issue":"3","key":"10.1016\/j.gastha.2026.101070_bib41","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/apt.70474","article-title":"Review article: seeing is believing-the eosinophilic oesophagitis endoscopic reference score can serve as a valuable clinical trial endpoint in eosinophilic oesophagitis","volume":"63","author":"Hirano","year":"2026","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastha.2026.101070_bib42","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1055\/a-1675-7860","article-title":"Determination of a treatment response threshold for the eosinophilic esophagitis endoscopic reference score","volume":"54","author":"Cotton","year":"2022","journal-title":"Endoscopy"},{"issue":"9","key":"10.1016\/j.gastha.2026.101070_bib43","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.14309\/ajg.0000000000003876","article-title":"An EREFS threshold of 2 or less is robust for assessing endoscopic response to treatment of eosinophilic esophagitis","volume":"121","author":"Reed","year":"2025","journal-title":"Am J Gastroenterol"},{"issue":"9","key":"10.1016\/j.gastha.2026.101070_bib44","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1016\/j.cgh.2022.11.004","article-title":"Higher body mass index is associated with decreased treatment response to topical steroids in eosinophilic esophagitis","volume":"21","author":"Ketchem","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"16","key":"10.1016\/j.gastha.2026.101070_bib45","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1001\/jama.2023.4855","article-title":"Randomized trials vs real-world evidence: how can both inform decision-making?","volume":"329","author":"Sheldrick","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.gastha.2026.101070_bib46","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/apt.12413","article-title":"Development and field testing of a novel patient-reported outcome measure of dysphagia in patients with eosinophilic esophagitis","volume":"38","author":"Dellon","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.gastha.2026.101070_bib47","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1053\/j.gastro.2010.05.001","article-title":"Oral viscous budesonide is effective in children with eosinophilic esophagitis in a randomized, placebo-controlled trial","volume":"139","author":"Dohil","year":"2010","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastha.2026.101070_bib48","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.cgh.2012.03.018","article-title":"Swallowed fluticasone improves histologic but not symptomatic responses of adults with eosinophilic esophagitis","volume":"10","author":"Alexander","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.gastha.2026.101070_bib49","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1053\/j.gastro.2019.03.014","article-title":"Efficacy of budesonide vs fluticasone for initial treatment of eosinophilic esophagitis in a randomized controlled trial","volume":"157","author":"Dellon","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.gastha.2026.101070_bib50","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.cgh.2014.07.034","article-title":"Predictors of response to steroid therapy for eosinophilic esophagitis and treatment of steroid-refractory patients","volume":"13","author":"Wolf","year":"2015","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Gastro Hep Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772572326001913?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772572326001913?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T12:01:13Z","timestamp":1791547273000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772572326001913"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":50,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026]]}},"alternative-id":["S2772572326001913"],"URL":"https:\/\/doi.org\/10.1016\/j.gastha.2026.101070","relation":{},"ISSN":["2772-5723"],"issn-type":[{"value":"2772-5723","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-World Clinical Efficacy of Food and Drug Administration\u2013Approved Budesonide Oral Suspension Across Histologic, Endoscopic, and Symptomatic Outcomes","name":"articletitle","label":"Article Title"},{"value":"Gastro Hep Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gastha.2026.101070","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Gastroenterological Association Institute.","name":"copyright","label":"Copyright"}],"article-number":"101070"}}